The Samantha Dickson Brain Tumour Trust and Cancer Research UK have teamed up to begin a multicentre Phase II clinical trial for a new surgical technique to treat brain tumours.
The GALA-5 trial being conducted at the University of Cambridge will enrol more than 60 patients with glioblastoma, to examine the tolerability and feasibility of two treatments used in combination.
Patients are due to be given 5-amino-levulinic acid, which causes a build-up of fluorescent chemicals that will make the tumour glow, to allow for more accurate and complete removal.
The second phase of the treatment involves inplanting wafers incorporated with carmustine, a chemotherapy drug, into the cavity to help remove any remaining tumour cells.
The partnership plans to conduct a large Phase III trial if the combination therapy is found to be safe and effective.
Related Companies
